| Old Articles: <Older 5571-5580 Newer> |
|---|
 |
The Motley Fool
April 21, 2009
Brian Richards |
Wonderful Company, but Is the Price Fair? Intuitive Surgical has one of the simplest -- and prettiest -- business models around. But is 24.6 times earnings -- its current multiple -- a "fair price?"   |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
The Motley Fool
April 20, 2009
Brian Orelli |
A Cheer and a Boo for Eli Lilly Cost-cutting is nice, but it doesn't slow down the drive toward the patent cliff. Lilly needs to be on the lookout for other partnerships to fill in the upcoming revenue holes. |
The Motley Fool
April 17, 2009
Robert Steyer |
The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity. |
The Motley Fool
April 17, 2009
Brian Orelli |
When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future? |
The Motley Fool
April 17, 2009
Brian Orelli |
Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half. |
The Motley Fool
April 17, 2009
Brian Orelli |
Intuitively Waiting Systems sales are down; no surprise there. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
April 16, 2009
Brian Orelli |
Icahn: Ludicrous and Arrogant Fun to read, but does he have the best intentions for long-term shareholders? |
Pharmaceutical Executive
April 1, 2009
David Zuckerman |
Make a Match Big Pharma is finally making a commitment to partner-based outsourcing. |
| <Older 5571-5580 Newer> Return to current articles. |
